CS
NMRA icon

Candriam SCA’s Neumora Therapeutics NMRA Stock Holding History

Candriam SCA’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-571,027
Closed -$6.05M – 701
2024
Q4 		$6.05M Sell
571,027
-105,217
-16% -$1.26M 0.03% 326
2024
Q3 		$8.93M Buy
+676,244
New +$7.89M 0.05% 282

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Candriam SCA's NMRA Position: Q1 2025 in Review

Candriam SCA sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 571,027 shares — an estimated $6.05M sold.

Candriam SCA first reported a position in NMRA in Q3 2024 and held it in 2 quarters. The position peaked at $8.93M in Q3 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Candriam SCA reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Candriam SCA sold 571,027 Neumora Therapeutics shares in Q1 2025, an estimated $6.05M.
  • Candriam SCA first reported a position in Neumora Therapeutics in Q3 2024 and held it in 2 quarters.
  • Candriam SCA's Neumora Therapeutics position peaked at $8.93M in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Candriam SCA's 13F filing for Q1 2025, filed 14 May 2025.